Zosano Pharma (NASDAQ:ZSAN) posted its quarterly earnings data on Monday. The biotechnology company reported ($3.80) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($4.80) by $1.00, Yahoo Finance reports.
Shares of Zosano Pharma (ZSAN) opened at $16.70 on Wednesday. Zosano Pharma has a twelve month low of $3.61 and a twelve month high of $46.40.
Separately, ValuEngine downgraded shares of Zosano Pharma from a “sell” rating to a “strong sell” rating in a report on Tuesday, February 27th.
A hedge fund recently raised its stake in Zosano Pharma stock. Vanguard Group Inc. lifted its position in shares of Zosano Pharma Corp (NASDAQ:ZSAN) by 20.8% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,217,323 shares of the biotechnology company’s stock after acquiring an additional 209,251 shares during the period. Vanguard Group Inc. owned approximately 3.11% of Zosano Pharma worth $1,716,000 as of its most recent filing with the Securities and Exchange Commission.
ILLEGAL ACTIVITY NOTICE: This piece of content was originally posted by Ticker Report and is the sole property of of Ticker Report. If you are reading this piece of content on another site, it was illegally stolen and reposted in violation of US & international copyright & trademark legislation. The original version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/3261861/zosano-pharma-zsan-announces-earnings-results.html.
About Zosano Pharma
Zosano Pharma Corporation is a clinical-stage specialty pharmaceutical company. The Company has developed a transdermal microneedle patch system to deliver its formulations of existing drugs through the skin for the treatment of a range of indications. Its microneedle patch system offers consistent drug delivery and improved ease of use and room-temperature stability.
Receive News & Ratings for Zosano Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zosano Pharma and related companies with MarketBeat.com's FREE daily email newsletter.